Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Frontiers in Medicine, May 2021, Volume 8, Article 550853
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis The Journal of Clinical Investigation, Volume 130, Issue 7, July 1, 2020
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography Antimicrobial Agents & Chemotherapy, July 2020, Volume 64, Issue 7
Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model Antimicrobial Agents & Chemotherapy, March 2020, Volume 64, Issue 3
Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Antimicrobial Agents & Chemotherapy, February 2020, Volume 64, Issue 2
Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats Antimicrobial Agents & Chemotherapy, October 2019, Volume 63, Issue 10
Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis Antimicrobial Agents & Chemotherapy, (2019) 63 (10) e01078-19
In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015–2017 Diagnostic Microbiology and Infectious Disease, Volume 95, Issue 4, December 2019, 114879
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus Antimicrobial Agents & Chemotherapy, (2019) 63 (6) e02616-18
The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis Antimicrobial Agents & Chemotherapy, (2019) 63 (4) e02291-18
In vitro activity of exebacase against contemporary beta-haemolytic streptococci recovered from US patients with bloodstream infections Presented at ECCMID 2022, April 23, 2022
Evaluation of the broth microdilution MIC method for exebacase against 100 beta-haemolytic streptococci Presented at ECCMID 2022, April 23, 2022
Assessment of exebacase MIC reproducibility: Thirty S. aureus isolates tested at three sites using three different commercial media lots Presented at ECCMID 2022, April 23, 2022
Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans Presented at North American Cystic Fibrosis Conference 2021, November 2, 2021
In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets Presented at ID Week 2021, September 29, 2021
Amurin Peptides: New Direct Lytic Agents (DLAs) with Broad Spectrum Antimicrobial Activity Against Gram-negative (GN) ESKAPE Pathogens Presented at World Microbe, June 2021
Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens Presented at World Microbe, June 2021
Lysin CF-370 In Vivo Efficacy Against a Carbapenem-Resistant Pseudomonas aeruginosa in a Rabbit Infective Endocarditis Model Presented at World Microbe, June 2021
PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models Presented at ID Week 2019, October 4, 2019
Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) Presented at ID Week 2019, October 3, 2019
